GGrantIndex
← Leaderboards

Manuel Hidalgo

Johns Hopkins University

Google Scholar ↗PubMed ↗ORCID ↗
$7,987,249
Attributed
$7,987,249
Total exposure
10
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.4M · FY2005–23
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$7,558,390 · 9
FDA$428,859 · 1

By mechanism

R01$4,266,875 · 4
R21$2,142,344 · 4
P30$1,283,031 · 1
R25$294,999 · 1

Top collaborators

No co-investigators on record.

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchResearch PersonnelProtocols DocumentationPharmaceutical PreparationsMedicalOperative Surgical ProceduresResourcesMalignant NeoplasmsPositioning AttributeClinical TrialsPre-ClinicalInstitutionProgramsSuccessResponsePropertyBaseStagingInnovationChemotherapyMultidisciplinaryBiologicalNeoplasm /Cancer ChemotherapyPredisposition

Grant awards (33)

Methods in Clinical Cancer Research Workshop$70,000
R25 · FY2023 · CA · contact PI
Methods in Clinical Cancer Research Workshop$224,999
R25 · FY2021 · CA · contact PI
Tailoring New Drugs in Pancreatic Cancer$121,828
R01 · FY2011 · CA · contact PI
RESEARCH PHARMACY$330,738
P30 · FY2010 · CA · contact PI
Tailoring New Drugs in Pancreatic Cancer$205,200
R01 · FY2010 · CA · contact PI
Individualized Treatment of Pancreatic Cancer$186,141
R01 · FY2010 · CA · contact PI
RESEARCH PHARMACY$335,286
P30 · FY2009 · CA · contact PI
Individualized Treatment of Pancreatic Cancer$282,659
R01 · FY2009 · CA · contact PI
Tailoring New Drugs in Pancreatic Cancer$282,416
R01 · FY2009 · CA · contact PI
RESEARCH PHARMACY$132,189
P30 · FY2009 · CA · contact PI
Individualized Treatment of Pancreatic Cancer$282,659
R01 · FY2008 · CA · contact PI
Tailoring New Drugs in Pancreatic Cancer$282,416
R01 · FY2008 · CA · contact PI
RESEARCH PHARMACY$161,606
P30 · FY2008 · CA · contact PI
Tailoring New Drugs in Pancreatic Cancer$326,952
R01 · FY2007 · CA · contact PI
Determinants of Response to ZD1839$312,869
R01 · FY2007 · CA · contact PI
Individualized Treatment of Pancreatic Cancer$282,587
R01 · FY2007 · CA · contact PI
Pharmacogenomics of Erlotinib$277,016
R21 · FY2007 · CA · contact PI
RESEARCH PHARMACY$161,606
P30 · FY2007 · CA · contact PI
Phase II Study of Rapamycin in Pancreatic Cancer$428,859
R01 · FY2006 · FD · contact PI
Determinants of Response to ZD1839 (1 R01-CA104900-01)$322,214
R01 · FY2006 · CA · contact PI
Individualized Treatment of Pancreatic Cancer$290,139
R01 · FY2006 · CA · contact PI
RESEARCH PHARMACY$161,606
P30 · FY2006 · CA · contact PI
Determinants of Response to ZD1839 (1 R01-CA104900-01)$329,968
R01 · FY2005 · CA
Pharmacogenomics of Erlotinib$297,040
R21 · FY2005 · CA
Pharmacodynamic-guided Dose-finding Study of Rapamycin$282,058
R21 · FY2005 · CA
Phase II Study of Rapamycin in Pancreatic Cancer$0
R01 · FY2005 · FD
Determinants of Response to ZD1839$329,968
R01 · FY2004 · CA
Pharmacodynamic-guided Dose-finding Study of Rapamycin$281,940
R21 · FY2004 · CA
Phase II Study of Rapamycin in Pancreatic Cancer$0
R01 · FY2004 · FD
Biological Evaluation of ZD1839 in Colon Cancer$285,350
R21 · FY2003 · CA
Biological Evaluation of CCI-779 in Brain Tumors$193,776
R21 · FY2003 · CA
Biological Evaluation of ZD1839 in Colon Cancer$301,225
R21 · FY2002 · CA
Biological Evaluation of CCI-779 in Brain Tumors$223,939
R21 · FY2002 · CA